Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.33 |
| ▸ | VEGFA | P15692 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476751 | 0.78 | SLC22A12 (0.46) | CYP11B1CYP11B2KDRPDGFRBALPL | |
| SCHEMBL1477267 | 0.76 | CYP11B1 (0.46) | CYP11B1CYP11B2GRM5 | |
| SCHEMBL1477955 | 0.75 | KDR (0.36) | CYP11B1CYP11B2KDRPDGFRBALPL | |
| SCHEMBL1476905 | 0.74 | CYP11B1 (0.51) | CYP11B1CYP11B2 | |
| SCHEMBL1476830 | 0.73 | CYP11B2 (0.41) | CYP11B1CYP11B2ALPLGRM5 | |
| SCHEMBL1478207 | 0.73 | CYP11B1 (0.39) | CYP11B1CYP11B2GRM5 | |
| SCHEMBL1477498 | 0.73 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM5 | |
| SCHEMBL1477509 | 0.73 | CYP11B1 (0.43) | CYP11B1CYP11B2RAF1GRM5 | |
| SCHEMBL1477679 | 0.73 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM5 | |
| SCHEMBL1479159 | 0.72 | MTOR (0.44) | CYP11B1CYP11B2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | CYP11B1 1606/4885CYP11B2 1328/4885KDR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.